Document:

EX-10.30

 Exhibit 10.30 
 

 
 September 21, 2021 

Jason Litten, M.D. 
 [***] 

Re:      Retention Agreement 

Dear Jason: 
 This letter sets forth the
substance of the retention agreement (the “Agreement”) that Artiva Biotherapeutics, Inc. (the “Company”) is offering to you. 

1.         Retention Period. 

(a)      Duties. From the date of this Agreement until March 31, 2022 (the
“Retention Period”), either (i) you will remain in your current role of Chief Medical Officer (“CMO”); or (ii) if the Company appoints a new CMO during the Retention Period, your employment will terminate
effective as of the date of such appointment (the “Employment Separation Date”), and you agree to continue to serve the Company as a consultant from the Employment Separation Date until the conclusion of the Retention Period
(or such earlier date as determined by the Company), on terms as determined by the Company and set forth in a consulting agreement to be entered into on or following the Employment Separation Date (the “Consulting Agreement”).
During the Retention Period, you agree to perform your job responsibilities or consulting services in good faith and to the best of your abilities. During the Retention Period, you must continue to comply with all of the Company’s policies and
procedures and with all of your statutory and contractual obligations to the Company, including, without limitation, your obligations under your Employee Confidential Information and Invention Assignment Agreement (a copy of which is attached hereto
as Exhibit A), which you acknowledge and agree are contractual commitments that remain binding upon you, both during and after the Retention Period. 

(b)      Salary and Benefits. From now through the Employment Separation Date, you
will continue to receive your current base salary for your services. Your benefits will continue on the terms and conditions now in effect until the Employment Separation Date. 

(c)      Retention Bonus. If you continue to satisfactorily provide continuous
full-time service to the Company as an employee or as a consultant pursuant to the Consulting Agreement through and until the conclusion of the Retention Period (or such earlier period as determined by the Company), then you will be eligible for a one-time retention bonus payment in the amount of $175,000, subject to applicable withholdings and deductions (the “Retention Bonus”). You will not be eligible to receive the Retention Bonus in the
event that, prior to the conclusion of the 

  Page
 2
 
  

 
Retention Period (i) you voluntarily resign from employment or from your consultancy, or you provide notice of your intent to resign from employment or from your consultancy, (ii) your
employment or consultancy is terminated for Cause (as defined below), or (iii) your employment is terminated without Cause prior to the Company’s appointment of a new CMO. Payment of the Retention Bonus shall be made subject to and
promptly following your execution and non-revocation of the Separation Date Release (as defined below) in accordance with Section 2. 

2.      Termination; Severance Benefits. Nothing in this Agreement alters your employment at will
status. Accordingly, during the Retention Period you are entitled to resign your employment with or without Cause or advance notice, and the Company may terminate your employment with or without Cause or advance notice. Although the Company is not
obligated to do so, in the event that (i) you resign from employment or from your consultancy at the conclusion of the Retention Period, (ii) your employment or your consultancy is terminated without Cause at the conclusion of the
Retention Period, or (iii) your consultancy is terminated without Cause after a new CMO has been appointed by the Company but prior to the conclusion of the Retention Period (any such termination date in (i) – (iii), the
“Separation Date”), and (iv) in each case, you timely execute a general release of claims in favor of the Company, as attached hereto as Exhibit B (the, “Separation Date Release”) on or within sixty
(60) days following the Separation Date, and allow it to become effective and otherwise comply with your obligations to the Company (including satisfactorily performing your duties during the Retention Period) (collectively, the
“Severance Preconditions”), then you will be eligible to receive the following severance benefits (the “Severance Benefits”), which shall extinguish, supersede and replace the severance benefits as stated in your
Employment Offer Letter Agreement dated as of August 11, 2019 (the “Prior Agreement”):  

(a)      Severance Payment. The Company will pay you, as severance, the equivalent
of your base salary in effect as of the Employment Separation Date for a period of six (6) months following the Retention Period (the “Severance Period”); provided, however, that in the event the Company has completed an
Initial Public Offering (“IPO”) during the Retention Period, the Severance Period shall increase to nine (9) months. This amount will be paid, subject to standard payroll deductions and withholdings, in equal installments on
the Company’s regular payroll schedule beginning within ten (10) days after the Effective Date of the Separation Date Release; provided that any such installments that would otherwise have been payable to you prior to the 60th
day following the Separation Date shall be accrued and paid to you in a lump sum in the first regular payroll period on or following the 60th day following the Separation Date. 

(b)    Annual Bonus. You will be eligible to receive a
pro-rated annual bonus payout, as determined based on the Company’s achievement of corporate goals, as determined by the Company’s Board of Directors (the “Board”) in its good faith
and absolute discretion. For clarity, if the Employment Separation Date occurs in 2022, you will be eligible to receive a bonus for the full year in 2021, and a bonus for 2022 prorated for the number of days you were employed during such year. If
your employment terminates in 2021, you will receive a bonus for 2021 prorated for the number of days you were employed during such year. Such bonus, if any, shall be paid, subject to standard payroll deductions and withholdings, at the time the
Company pays such bonuses to other similarly executives. 

  Page
 3
 
  

 (c)      Health Insurance. To the
extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company’s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense following
the Separation Date. Later, you may be able to convert to an individual policy through the provider of the Company’s health insurance, if you wish. You will be provided with a separate notice describing your rights and obligations under COBRA.
As an additional severance benefit under this Agreement, provided that you satisfy the Severance Preconditions set forth above and timely elect continued coverage under COBRA, then the Company shall reimburse you for the COBRA premiums to continue
your health insurance coverage (including coverage for eligible dependents, if applicable) through the period (the “COBRA Premium Period”) starting on the Employment Separation Date and ending on the earliest to occur of:
(i) the number of months following the Employment Separation Date that is equal to the Severance Period; (ii) the date you become eligible for group health insurance coverage through a new employer; or (iii) the date you cease to be
eligible for COBRA coverage for any reason. You must timely pay your premiums, and then provide the Company with proof of same, to obtain reimbursement for your COBRA premiums under this Section. In the event you become covered under another
employer’s group health plan or otherwise cease to be eligible for COBRA during the COBRA Premium Period, you must immediately notify the Company in writing of such event. 

(d)      Stock Options. You were granted options to purchase shares of the
Company’s common stock pursuant to the Company’s 2020 Equity Incentive Plan (the “Plan”). Under the terms of the Plan and your stock option grants, vesting will cease as of the Separation Date. Your options will continue
to be governed by the terms of the applicable grant notices, stock option agreements and the Plan. Notwithstanding the foregoing, (x) in the event that you are eligible for the Severance Benefits and (y) you have entered into a lock-up agreement between you and the underwriters for an initial public offering of the Company’s Common Stock, which lock-up agreement is then in effect, then subject
to approval of the Board, the exercise period for your options that have vested as of the termination of your employment or consultancy shall be extended such that you will have ninety (90) days after the expiration of such lock-up agreement to exercise your vested options, but in no event shall the exercise period for your options be extended beyond the applicable expiration date for such options. You understand and agree that such
amendment to your option grant to provide for an extended exercise period may convert any options that were granted as “incentive stock options” under Section 422 of the Internal Revenue Code of 1986 (as amended) to no longer be
“incentive stock options.” The loss of “incentive stock options” status has tax implications that you should discuss with your own tax and legal advisors. If you do not wish to extend the post-termination exercise window of
the options, the options will retain “incentive stock options” status as long as you exercise the options within three (3) months following your Separation Date.” 

(e)      Restricted Stock. You also were granted 90,000 shares of restricted
Common Stock (the “Stock Award”) under the terms of the Restricted Stock Purchase Agreement between you and the Company, dated August 23, 2019 (the “Restricted Stock Award Agreement”). The Stock Award is
subject to vesting at the rate of 25% of the shares of Common Stock per year, with a repurchase right in favor of the Company with respect to any 

  Page
 4
 
  

 
unvested shares as of the Separation Date. The vesting of your Stock Award will cease as of the Separation Date. Notwithstanding anything to the contrary set forth in the Stock Award Agreement,
in the event that you are eligible for the Severance Benefits, and subject to approval of the Board, the Company will not exercise its Repurchase Option under the Stock Award Agreement for 16,875 of the shares of Common Stock subject to the Stock
Award. 
 3.    Definition of Cause. For purposes of this Agreement, “Cause” means the
occurrence of any one or more of the following: (i) your conviction of, or plea of no contest, or commission of any felony or any crime involving fraud, embezzlement, dishonesty or moral turpitude; (ii) your attempted commission of, or
participation in, a fraud, embezzlement or act of dishonesty (or an attempted fraud or act of dishonesty) that results in (or could result in) material harm to the Company, including but not limited to material harm to reputational interests;
(iii) your violation of a fiduciary duty or duty of loyalty owed to the Company; (iv) your material breach of any contract or agreement between you and the Company, or any material Company policies that are disclosed or otherwise made
available in writing to you prior to such breach; (v) persistent neglect of your job duties or consulting services, which is not cured within fifteen (15) calendar days after you are provided written notice by the Company (provided, that
such written notice and opportunity to cure are not required if your performance or neglect is not reasonably susceptible to being cured); or (vi) your gross misconduct or material failure to comply with a reasonable written instruction of the
Company. 
 4.     409A. The intent of the parties is that payments and benefits under this
letter agreement be exempt from or comply with Section 409A of the Code, to the extent subject thereto, and, accordingly, to the maximum extent permitted, this letter agreement shall be interpreted and administered to be in compliance therewith
and each of the parties shall report the payments and benefits under this letter agreement as exempt from or compliant with Section 409A of the Internal Revenue Code of 1986 as amended (“Section 409A). All
payments provided hereunder are intended to constitute separate payments for purposes of Treasury Regulation Section 1.409A-2(b)(2). If the Company determines that any benefits provided under this
Agreement constitute “deferred compensation” under”), such benefits will not commence in connection with your termination of employment or consultancy unless such termination also qualifies as a “separation from service”
with the Company within the meaning of Treasury Regulation Section 1.409A- 1(h) (without regard to any permissible alternative definition thereunder) (“Separation from Service”). If the Company determines that any benefits
provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee” of the Company or any affiliate (or any successor entity thereto) within the meaning of
Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier of (i) the date that is six (6) months and one (1) day after the date of
your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment Date”), and the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum
of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date, without any adjustment on account of such delay, and (B) continue the benefit payments in accordance with any applicable payment schedules
set forth for the balance of the period specified herein. In addition to the above, to the extent required to comply with Section 409A 

  Page
 5
 
  

 
and the applicable regulations and guidance issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Separation Date Release spans two (2) calendar
years, your Severance Benefits shall commence to be paid in installments on the first regularly scheduled payroll date that occurs in the calendar year following the calendar year of the Effective Date of the Separation Date Release. To the extent
that any reimbursements under this Agreement are taxable to you, any such reimbursement payment due to you shall be paid as promptly as practicable consistent with the Company’s practice following appropriate itemization and substantiation of
expenses incurred, and in all events on or before the last day of the taxable year following the taxable year in which the related expense was incurred. The in-kind benefits and reimbursements under this
Agreement, are not subject to liquidation or exchange for another benefit, and the amount of such benefits or reimbursements that you receive in one taxable year shall not affect the amount of such benefits or reimbursements that you receive in any
other taxable year. 
 5.      No Other Compensation or Benefits. You acknowledge that, except
as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits before or after the Separation
Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested options. 

6.      Confidentiality. The provisions of this Agreement will be held in strictest confidence by
you and will not be publicized or disclosed by you in any manner whatsoever; provided, however, that: (a) you may disclose this Agreement in confidence to your immediate family and to your attorneys, accountants, tax preparers and
financial advisors; and (b) you may disclose this Agreement insofar as such disclosure may be necessary to enforce its terms or as otherwise required by law. In particular, and without limitation, you agree not to disclose the terms of this
Agreement to any current or former Company employee or independent contractor. 
 7.      No
Voluntary Adverse Action. You agree that you will not voluntarily (except in response to legal compulsion or as permitted under the Protected Activities section below) assist any person in bringing or pursuing any proposed or pending
litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents. 

8.      Cooperation. You agree to cooperate fully with the Company in connection with its actual
or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters arising from events, acts, or failures to act that occurred during the period of your employment by the Company. Such
cooperation includes, without limitation, making yourself available to the Company upon reasonable notice, without subpoena, to provide complete, truthful and accurate information in witness interviews, depositions, and trial testimony. The Company
will reimburse you for reasonable out-of-pocket expenses you incur in connection with any such cooperation (excluding foregone wages) and will make reasonable efforts to
accommodate your scheduling needs. 

  Page
 6
 
  

 9.      No Admissions. You understand and agree
that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission. 

10.    Representations. You hereby represent that you have been paid all compensation owed and for all hours
worked through the date you sign this Agreement, have received all the leave and leave benefits and protections for which you are eligible pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise, and have not
suffered any on-the-job injury for which you have not already filed a workers’ compensation claim. 

11.  Dispute Resolution. You and the Company agree that any and all disputes, claims, or controversies of any
nature whatsoever arising from, or relating to, this Agreement or its interpretation, enforcement, breach, performance or execution, your employment or the termination of such employment (including, but not limited to, any statutory claims)
(collectively, “Claims”, each a “Claim”), shall be resolved, pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by
law, by final, binding and confidential arbitration in San Diego, California (or another mutually acceptable location) conducted before a single neutral arbitrator by JAMS, Inc. (“JAMS”) or its successor, under the then
applicable JAMS Arbitration Rules and Procedures for Employment Disputes (available at http://www.jamsadr.com/rules-employment-arbitration/). By agreeing to this arbitration procedure, both you and the Company waive the right to have any Claim resolved through a trial by jury or judge or an administrative proceeding. You will have the right to
be represented by legal counsel at any arbitration proceeding, at your own expense. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims
brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and the applicable law(s) are not preempted by the Federal
Arbitration Act or otherwise invalid (collectively, the “Excluded Claims”). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a
court, while any other claims will remain subject to mandatory arbitration. The arbitrator shall have sole authority for determining if a Claim is subject to arbitration, and any other procedural questions related to the dispute and bearing on the
final disposition. In addition, the arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and
(b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which
the award is based. The Company shall pay all JAMS arbitration fees. Nothing in this Agreement shall prevent you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration. Any
awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

  Page
 7
 
  

 12.    Miscellaneous. This Agreement, including its
Exhibits, constitute the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other
than those expressly contained herein, and it supersedes any other such promises, warranties or representations, including the Prior Agreement. You agree and acknowledge that there are no circumstances as of the date of this Agreement that
constitute, and nothing contemplated in this Agreement shall be deemed for any purpose to be or to create, an involuntary termination without Cause, including for purposes of the Prior Agreement, or any other severance or change in control plan,
agreement or policy maintained by the Company. You further hereby expressly waive any claim or right you may have as of the date of this Agreement (if any) to assert that this Agreement, or any other condition or occurrence, forms the basis for a
without Cause termination for any purpose, including for purposes of the Prior Agreement, or any other severance or change in control plan, agreement or policy maintained by the Company. This Agreement may not be modified or amended except in a
writing signed by both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their
heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be
modified by the court so as to be rendered enforceable to the fullest extent permitted by law, consistent with the intent of the parties. This Agreement will be deemed to have been entered into and will be construed and enforced in accordance with
the laws of the State of California without regard to conflict of laws principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement shall be in writing and shall not
be deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and facsimile signatures will suffice as original signatures. 

If this Agreement is acceptable to you, please sign below and return the original to me. You have
twenty-one (21) calendar days to decide whether you would like to accept this Agreement, and the Company’s offer contained herein will automatically expire if you do not sign and return it within
this timeframe. 
 We wish you the best in your future endeavors. 
  

			
	Sincerely,
	
	By: /s/ Fred Aslan                              
                  
	          	 	Fred Aslan, M.D.
		 	President and Chief Executive Officer

  Page
 8
 
  

 I HAVE READ, UNDERSTAND AND
AGREE FULLY TO THE FOREGOING AGREEMENT: 
  

	
	 /s/ Jason Litten

	 Jason B. Litten, M.D.
  

9/21/2021

	Date

 EXHIBIT A 

EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION
ASSIGNMENT AGREEMENT 

 EXHIBIT B 

SEPARATION DATE RELEASE 

(to be signed and returned to the Company on or within twenty-one (21) days after the 

Separation Date) 
 In
exchange for the Severance Benefits to be provided to me by Artiva Biotherapeutics, Inc. (the “Company”) pursuant to that certain letter Retention Agreement with the Company dated [DATE] (the “Agreement”), I
hereby provide the following Separation Date Release (this “Release”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement. 

I hereby represent that I have been paid all compensation owed and for all hours worked through the date I sign this Release, have received
all the leave and leave benefits and protections for which I am eligible pursuant to the Family and Medical Leave Act, the California Family Rights Act, or otherwise, and have not suffered any on-the-job injury for which I have not already filed a workers’ compensation claim. I acknowledge that, other than the Severance Benefits to be provided to me pursuant to the Agreement upon satisfaction
of the Severance Preconditions, I have not earned and will not receive from the Company any additional compensation (including base salary, bonus, incentive compensation, or equity), severance, or benefits, with the exception of any vested right I
may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account) or any vested options. 
 I hereby
generally and completely release the Company, and its affiliated, related, parent and subsidiary entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors,
insurers, affiliates, and assigns from any and all claims, liabilities, demands, causes of action, and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring at any time
prior to and including the date I sign this Release. This general release includes, but is not limited to: (a) all claims arising out of or in any way related to my employment with the Company or the termination of that employment; (b) all
claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests
in the Company; (c) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (d) all tort claims, including claims for fraud, defamation, emotional distress, and discharge
in violation of public policy; and (e) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other claims arising under the federal Civil Rights Act of 1964 (as
amended), the federal Americans with Disabilities Act of 1990, the California Labor Code (as amended), the California Family Rights Act, the Age Discrimination in Employment Act (“ADEA”) and the California Fair Employment and
Housing Act (as amended). Notwithstanding the foregoing, I am not releasing the Company hereby from any obligation to indemnify me pursuant to the Articles and Bylaws of the Company, any valid fully executed indemnification agreement with the
Company, applicable 

 Page 2 
  

 
law, or applicable directors and officers liability insurance. Also, excluded from this Release are any claims that cannot be waived by law. 

I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I have under the ADEA, and that the consideration given for
the waiver and releases I have given in this Release is in addition to anything of value to which I was already entitled. I further acknowledge that I have been advised, as required by the ADEA, that: (a) my waiver and release does not apply to
any rights or claims that arise after the date I sign this Release; (b) I should consult with an attorney prior to signing this Release (although I may choose voluntarily not to do so); (c) I have
twenty-one (21) days to consider this Release (although I may choose voluntarily to sign it sooner); (d) I have seven (7) days following the date I sign this Release to revoke this Release (in a
written revocation sent to the Company); and (e) this Release will not be effective until the date upon which the revocation period has expired, which will be the eighth day after I sign this Release provided that I do not revoke it (the
“Effective Date”). 
 In giving the release herein, which includes claims which may be unknown to me at present, I
acknowledge that I have read and understand Section 1542 of the California Civil Code, which reads as follows: 

“A general release does not extend to claims that the creditor or releasing party does not know or
suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.” 

I hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect
with respect to my release of claims herein, including but not limited to my release of unknown claims. 
 I understand that nothing in this
Release limits my ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the California Department of
Fair Employment and Housing, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (“Government Agencies”). I further understand this Release does not limit my ability to
communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this
Release does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to
individual relief based on any claims that I have released and any rights I have waived by signing this Release. 
 [Signature page to
follow] 

 Page 3 
  

 This Release, together with the Agreement (and its exhibits) constitutes the entire agreement
between me and the Company with respect to the subject matter hereof. I am not relying on any representation not contained herein or in the Agreement. 

UNDERSTOOD, ACCEPTED, AND AGREED: 

 

                       
                                         
                         
 Jason
B. Litten, M.D. 
  

                       
                                         
                         
 DateEX-10.31

 Exhibit 10.31 
 

 
 December 6, 2021 
 Chris Horan 

Private & Confidential 
  

	Re:	 Employment Offer Letter 

Dear Chris, 
 On behalf of Artiva
Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start
date, which will be on December 31, 2021 (the “Start Date”). 

1.        Employment Position; Duties. You will be employed as the
Company’s Chief Technical Operations Officer (“CTO”). As CTO, you will have those duties and responsibilities as are customary for this position and as may be directed by the Company. Your position will be remote, and you will
work from your home office. During your employment, you will devote your full-time best efforts to the business of the Company. 

2.            Base Salary; Employee Benefits and Business
Expenses. 
 (a)            Base Salary. Your initial
base salary will be paid at the annual rate of $400,000.00, less standard payroll deductions and tax withholdings. Effective upon the closing of the Company’s initial public offering (the “IPO”), your base salary will increase
to $450,000.00. Your base salary will be paid on the Company’s normal payroll schedule. As an exempt salaried employee, you will be required to work the Company’s normal business hours, and such additional time as appropriate for your work
assignments and position. You will not be eligible for extra payment under the overtime laws. 

(b)            Employee Benefits. Effective the first day
of the month following your Start Date, you will be eligible to participate in the Company’s benefit program. The current benefit program includes medical, dental and vision coverage. You may also elect to participate in the Company’s 401K
plan. The Company does not contribute currently to the 401K plan. You will also be eligible to accrue Paid Time Off (PTO) at a rate of 9 hours per pay period, or a total of 216 hours annually. Details of the PTO policy and other benefits are
provided in the Company’s Employee Handbook. 

(c)          Business Expenses. Your legitimate and documented
business expenses will be reimbursed by the Company as provided under its business expense reimbursement policies. Your reimbursable business expenses will include reasonable costs of travel from your home office to and from San Diego as required
for your role and as agreed upon between yourself and the Company. 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  1	 

 3.        Annual Bonus. In
addition to base salary, you will be eligible to earn discretionary incentive compensation at an annual target amount of thirty percent (30%) of your base salary in effect during the bonus year. Effective upon the closing of the Company’s IPO,
your annual target bonus will increase to forty (40%) of your base salary in effect during the bonus year. With respect to the annual incentive compensation program, the Company’s executive team will evaluate and recommend specific annual
corporate and/or individual performance targets, metrics and/or management-by-objectives (“MBOs”), to be finalized and approved by the Company’s
Board of Directors (the “Board”), as part of its annual compensation review process. Annual bonuses are paid on an annual basis, after the close of the fiscal year and after determination by the Board of (a) the level of
achievement of the applicable individual and corporate performance targets, metrics and/or MBOs, and (b) the amount of the annual incentive compensation earned by you (if any). No amount of annual incentive compensation is guaranteed and, in
addition to the other conditions for earning such compensation, you must remain an employee of the Company in good standing on the scheduled annual incentive compensation payment date in order to earn or be eligible for any annual incentive
compensation. Except as expressly provided in this Agreement or communicated to you in writing by a duly authorized officer of the Company, you will not be entitled to any other incentive compensation, commission, or other bonus programs. 

4.            Equity Award: Upon joining the Company, and
subject to approval by the Company’s Board of Directors, you will be eligible to receive a stock option grant to purchase 340,000 shares of the Company’s common stock (the “Options”), pursuant to the Company’s 2020
Equity Incentive Plan (the “Plan”). The purchase price per share of the Options will be equal to the fair market value of the Company’s common stock on the date of grant. Twenty-five percent (25%) of the Options will vest on
the one-year anniversary of your Start Date and the remainder will vest in equal monthly installments thereafter over the next thirty-six (36) months, subject to
your Continued Service (as defined in the Plan) with the Company through each such vesting date. The terms of the Options will be governed by the Plan and the applicable option award agreement between you and the Company. In addition, provided that
you become an employee and commence your Start Date by no later than December 31, 2021, you may be eligible to receive, subject to approval by the Board, additional equity awards under any annual equity award programs the Company may adopt in
2022. Any such annual equity award will not be pro-rated based upon your Start Date. 

5.            Signing Bonus: If you accept and commence
employment with the Company, the Company will provide you with a signing bonus of $100,000 (the “Signing Bonus”). The Signing Bonus will be advanced to you prior to it being earned on the second paycheck following your Start Date,
and will be subject to the usual payroll deductions and tax withholdings. You will not fully earn the Signing Bonus unless you remain continuously employed with the Company through the 24-month anniversary of
your Start Date. The Signing Bonus is subject to the following repayment obligations: (i) if you voluntarily resign, or are terminated by the Company for Cause (as defined in the Plan, or any successor or replacement plan) in each case prior to
the 12-month anniversary of your Start Date, then you will be obligated to repay to the Company the full amount of the Signing Bonus; and (ii) if you voluntarily resign, or are terminated by the Company
for Cause, in each case anytime between the 13- and 24-month anniversary of your Start Date, then you will be obligated to repay to the Company a pro-rated amount of the Signing Bonus based on the length of your service with the Company. Such repayment shall be made within 30 days following your employment termination or resignation date, as applicable. 

6.            Compliance with Confidentiality Agreement and
Company Policies. As a condition of employment, you shall sign and comply with the Company’s standard form of Employee Confidential 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  2	 

 
Information and Invention Assignment Agreement (the “Confidentiality Agreement”). The Confidentiality Agreement shall be deemed fully incorporated into this Agreement by
reference. 

7.            COVID-19
Vaccination. The Company requires COVID-19 vaccinations as a condition of employment. If you have any questions about COVID-19 vaccinations, you should consult a
trusted healthcare provider. Unless an exemption applies, the Company requires that all employees be fully vaccinated before their Start Date. An employee is considered “fully vaccinated” if at least 14 days or a period specified by the
vaccine’s manufacturer have elapsed since the employee received the last dose of a vaccine that the FDA has authorized for use in the United States. FDA-authorized vaccinations include vaccinations that
have been authorized pursuant to an Emergency Use Authorization. For an employee fully vaccinated outside of the United States, the vaccination must be listed for emergency use by the World Health Organization (“WHO”). 

To establish that you are fully vaccinated, we require that you provide evidence of immunization by presenting a completed COVID-19 Vaccine Card or documentation from an authorized healthcare provider or pharmacy proving that you have received the COVID-19 vaccine. Please submit these documents to
Brandon Saunders at bsaunders@artivabio.com or via the Company’s HR portal. The Company must receive this documentation prior to your projected Start Date. 

Employees who have i) a qualifying medical condition that contraindicates the vaccination, or ii) who object to being vaccinated on the basis of a
sincerely held religious belief or practice, may contact Jennifer Bush at jbush@artivabio.com. The Company regards all such information as confidential. 

8.            Protection of Third-Party Information and Outside
Activities. 
 (a)        Third Party Information. In your work for the
Company, you will be expected not to make any unauthorized use or disclosure of any confidential information or materials, including trade secrets, of any former employer or other third party; and not to violate any lawful agreement that you may
have with any third party. By signing this Agreement, you represent that you are able to perform your job duties within these guidelines, and you are not in unauthorized possession or control of any confidential documents, information, or other
property of any former employer. In addition, you represent that you have disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) that may limit your ability to perform your duties to the Company
or that could present a conflict of interest with the Company, including but not limited to disclosure (and a copy) of any contractual restrictions on solicitations or competitive activities. 

(b)            Outside Activities. During your employment
by the Company, you may engage in civic and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or
present a conflict of interest with the Company or its affiliates. Subject to the restrictions set forth herein, and only with prior written disclosure to and written consent of the Board, you may engage in other types of business or public
activities. The Board may withdraw such consent, if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the business interests of the Company or its affiliates or conflict with your duties to the
Company. 

(c)            
Non-Competition. During your employment by the Company, you will not, without the express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee,
partner, proprietor, investor, joint venturer, associate, representative or consultant of any person or entity engaged in, or planning or preparing to engage in, business activity 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  3	 

 
competitive with any line of business engaged in (or planned to be engaged in) by the Company or its affiliates; provided, however, that you may purchase or otherwise acquire up to (but not more
than) one percent (1%) of any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. In addition, you will be subject to
certain restrictions (including restrictions continuing after your employment ends) under the terms of your Confidentiality Agreement. 

9.              
At-Will Employment Relationship. Your employment relationship with the Company is employment at-will. Accordingly, you may terminate your employment with the Company at any time and for any reason
whatsoever simply by notifying the Company; and the Company may terminate your employment at any time with or without Cause (as defined below) or prior notice. In addition, the Company retains the discretion to modify your other employment terms
from time to time, including but not limited to your position, duties, reporting relationship, work location, compensation (including base salary and incentive compensation terms), and benefits. 

10.            Severance. 

(a)            Pre-IPO
Severance for Qualifying Termination. If (i) your employment is terminated by the Company without Cause (as defined in the Plan, or any successor or replacement plan), other than due to your death or disability, and (ii) you satisfy
the Release Requirement (defined below), then you will receive severance pay in the form of continuation of your final monthly base salary for six (6) months, plus six (6) months of benefits coverage under COBRA, less standard payroll
deductions and tax withholdings. 
 (b)            Post-IPO Severance upon Termination without Cause or Resignation with Good Reason. If (i) your employment is terminated by the Company without Cause (as defined in the Plan), other than due to your death or
disability, or you terminate your employment with Good Reason (as defined in the Plan), (ii) you satisfy the Release Requirement (defined below), and (iii) comply with your obligations under the Confidentiality Agreement, then you will receive
the following “Severance Benefits”: (A) You will receive severance pay in the form of continuation of your final monthly base salary for a period of nine (9) months following your termination date, less standard payroll deductions and
tax withholdings (the “Severance Payments”). Subject to Section 10(e), the Severance Payments will be paid in equal installments on the Company’s regular payroll schedule in effect following your termination date, with such
payments to begin on the first regular payroll date following the Release Effective Date (as defined below). If the Severance Payments do not commence with the first regular payroll date following your termination date because the Release Effective
Date is later than such first payroll date, the first installment of the Severance Payments you receive will be a “catch up” payment in the total amount of the Severance Payments you would have received through such payroll date if such
payments had begun with the first payroll date after your termination date; (B) In addition, if you timely elect continued coverage under COBRA, the Company will pay the COBRA premiums for you and your eligible dependents until the earlier of
either: (i) a period ending nine (9) months following your termination date or, (ii) the date on which you are no longer eligible for COBRA coverage (such period, the “COBRA Payment Period”). Notwithstanding the foregoing,
if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the
Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you or your qualifying family members elect COBRA continuation coverage (the “Health Care Benefit
Payment”). The Health Care Benefit Payment shall be paid in installments on the same schedule 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  4	 

 
that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance
premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the COBRA Payment Period. For purposes of this Agreement, (i) references to COBRA shall be deemed to
refer also to analogous provisions of state law and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan,
which amounts, if any, are your sole responsibility; and (C) The vesting and exercisability of all outstanding and unvested equity awards covering the Company’s common stock that are held by you as of immediately prior to the termination
date, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in accordance with their applicable vesting schedules as if you had completed an additional
three (3) months of service with the Company as of the termination date. 

(c)            Post-IPO
Severance upon Termination without Cause or Resignation with Good Reason in Connection with a Change of Control. If (i) your employment is terminated by the Company without Cause (as defined in the Plan), other than due to your death or
disability, or you terminate your employment with Good Reason (as defined in the Plan), in each case within a period commencing three (3) months before, or twelve (12) months after a Change of Control (as defined in the Plan), (ii) you
satisfy the Release Requirement (defined below), and (iii) comply with your obligations under the Confidentiality Agreement, then you will receive the following “Change of Control Severance Benefits”: (A) You will receive severance
pay in the form of continuation of your final monthly base salary for a period of twelve (12) months following your termination date, less standard payroll deductions and tax withholdings (the “Change of Control Severance Payments”).
Subject to Section 10(e), the Severance Payments will be paid in equal installments on the Company’s regular payroll schedule in effect following your termination date, with such payments to begin on the first regular payroll date
following the Release Effective Date (as defined below). If the Severance Payments do not commence with the first regular payroll date following your termination date because the Release Effective Date is later than such first payroll date, the
first installment of the Severance Payments you receive will be a “catch up” payment in the total amount of the Severance Payments you would have received through such payroll date if such payments had begun with the first payroll date
after your termination date; (B) In addition, if you timely elect continued coverage under COBRA, the Company will pay the COBRA premiums for you and your eligible dependents until the earlier of either: (i) a period ending twelve
(12) months following your termination date or, (ii) the date on which you are no longer eligible for COBRA coverage (such period, the “COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its sole
discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company
shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you or your qualifying family members elect COBRA continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit
Payment shall be paid in installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA
insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the COBRA Payment Period. For purposes of this Agreement, (i) references to COBRA shall be
deemed to refer also to analogous provisions of state law and (ii) any applicable insurance premiums that are paid by the Company shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care
reimbursement plan, which amounts, if any, are your sole responsibility; (C) In addition, you will receive your full target Annual Bonus 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  5	 

 
for the fiscal year in which your employment terminates, payable on the first regular payroll date following the Release Effective Date, provided that the Release Requirement has been satisfied;
and (D) Effective as of the later of the termination date or the effective date of the Change of Control, the vesting and exercisability of all outstanding and unvested equity awards covering the Company’s common stock that are held by you
as of immediately prior to such date, to the extent such equity awards would otherwise have vested solely conditioned on your continued services with the Company, shall accelerate vesting in full. For the avoidance of doubt, in no event shall you be
entitled to benefits under both Section 10(b) and this Section 10(c). If you are eligible for benefits under both Section 10(b) and this Section 10(c), you shall receive the benefits set forth in this Section 10(c) and such
benefits shall be reduced by any benefits previously provided to you under Section 10(b). 

(d)            Release Requirement. To be eligible for the
Severance Benefits pursuant to Section 10(a)-(b) and the Change of Control Severance Benefits pursuant to Section 10(c) above, you must satisfy the following release requirement (the “Release Requirement”): You must timely
execute and return to the Company a signed and dated general release of all known and unknown claims in a separation agreement acceptable to the Company (the “Release and Waiver”) within the applicable deadline set forth therein, but in no
event later than forty-five (45) calendar days following your termination date, and permit the Release and Waiver to become effective and irrevocable in accordance with its terms (such effective date of the Release and Waiver, the “Release
Effective Date”). No Severance Benefits or Change of Control Severance Benefits will be paid or provided hereunder prior to such Release Effective Date. You may be required by the separation agreement to provide reasonable transitional services
as a condition to receiving the Severance Benefits and/or the Change of Control Severance Benefits. 

(e)            Other. You will not be eligible for any
Severance Benefits or Change of Control Severance Benefits under any circumstances other than those described herein, including circumstances in which your employment is terminated for Cause, you terminate your employment for any reason other than
Good Reason, or your employment terminates due to your death or disability. In addition, if you materially breach any continuing obligations to the Company (including, but not limited to, any material breach of this Agreement or any material breach
of the Confidentiality Agreement) during the period of time that you are receiving any Severance Benefits or Change of Control Severance Benefits, as applicable, you will forfeit your entitlement to any then unpaid Severance Benefits and/or Change
of Control Severance Benefits, as applicable, and the Company’s obligation to continue to pay or provide such Severance Benefits and Change of Control Severance Benefits will immediately terminate as of the date of your material breach and you
will be required to return to the Company any Severance Benefits and Change of Control Severance Benefits already provided to you. 

(f)            IRS Code Section 409A.
All payments provided hereunder are intended to constitute separate payments for purposes of Treasury Regulation Section 1.409A-2(b)(2). If the Company determines that any benefits provided under this
Agreement constitute “deferred compensation” under Section 409A of the Internal Revenue Code of 1986 as amended (“Section 409A”), such benefits will not commence in connection with your termination of employment unless
such termination also qualifies as a “separation from service” with the Company within the meaning of Treasury Regulation Section 1.409A-1(h) (without regard to any permissible alternative
definition thereunder) (“Separation from Service”). If the Company determines that any benefits provided under this Agreement constitute “deferred compensation” under Section 409A and you are a “specified employee”
of the Company or any affiliate (or any successor entity thereto) within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of your Separation from Service, then the payment of any such benefits shall be delayed until the earlier

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  6	 

 
of (i) the date that is six (6) months and one (1) day after the date of your Separation from Service, or (ii) the date of your death (such date, the “Delayed Payment
Date”), and the Company (or the successor entity thereto, as applicable) shall (A) pay to you a lump sum amount equal to the sum of the benefit payments that otherwise would have been paid to you on or before the Delayed Payment Date,
without any adjustment on account of such delay, and (B) continue the benefit payments in accordance with any applicable payment schedules set forth for the balance of the period specified herein. In addition to the above, to the extent
required to comply with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for you to execute (and not revoke) the applicable Release and Waiver spans two (2) calendar years, your
Severance Benefits and/or Change of Control Severance Benefits shall commence to be paid in installments on the first regularly scheduled payroll date that follows the effective date of the Release and Waiver and which also occurs during the second
permitted calendar year for returning the effective Release and Waiver. 

11.            Section 280G; Limitations on Payment. 

(a)            If any payment or benefit you will or may receive
from the Company or otherwise (a “280G Payment”) would (i) any constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed
by Section 4999 of the Code (the “Excise Tax”), then any such 280G Payment provided pursuant to this Agreement (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount” shall be
either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount
(i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results
in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required
pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest economic
benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). 

(b)            Notwithstanding any provision of Section 12(a)
to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A,
then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (i) as a first priority, the modification shall preserve to
the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis; (ii) as a second priority, Payments that are contingent on future events (e.g., being terminated
without Cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (iii) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be
reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A. 

(c)        Unless you and the Company agree on an alternative accounting firm or law
firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the Change of Control transaction shall perform the foregoing calculations. If the accounting firm so engaged by the
Company is serving as accountant or auditor for the individual, entity 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  7	 

 
or group effecting the Change in Control transaction, the Company shall appoint a nationally recognized accounting or law firm to make the determinations required by this Section 9. The
Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder. The Company shall use commercially reasonable efforts to cause the accounting or law firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which your right to a 280G Payment becomes reasonably likely to
occur (if requested at that time by you or the Company) or such other time as requested by you or the Company. 

(d)            If you receive a Payment for which the Reduced
Amount was determined pursuant to clause (x) of Section 12(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you agree to promptly return to the Company a sufficient
amount of the Payment (after reduction pursuant to clause (x) of Section 12(a) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause
(y) of Section 12(a), you shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. 

12.        Dispute Resolution. To ensure the rapid and economical resolution of
disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating
to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment with the Company, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. §1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (“JAMS”) or its successors by a single arbitrator. The arbitration will
be held in San Diego, California, or such other location as then-agreed by the parties. Both you and the Company acknowledge that by agreeing to this arbitration procedure, you each waive the right to resolve any such dispute through a trial
by jury or judge or administrative proceeding. 
 Any such arbitration proceeding will be governed by JAMS’ then
applicable rules and procedures for employment disputes, which will be provided to you upon request and also currently available at http://www.jamsadr.com/rules-employment-arbitration/. In any such proceeding, the arbitrator shall
(a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written arbitration decision including the arbitrator’s essential
findings and conclusions and a statement of the award. You and the Company shall be entitled to all rights and remedies that would be entitled to pursue in a court of law. Nothing in this Agreement is intended to prevent either the Company or you
from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration pursuant to applicable law. You and the Company both have the right to be represented by legal counsel at any arbitration
proceeding, at each party’s own expense. The Company shall pay all filing fees in excess of those which would be required if the dispute were decided in a court of law and shall pay the arbitrator’s fees and any other fees or costs unique
to arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. 

13.        General. This Agreement, along with the Confidentiality Agreement,
forms the complete and exclusive statement of your agreement with the Company regarding the subject matter hereof. It supersedes and replaces any other agreements or promises made to you by anyone concerning your employment compensation, benefits
and/or terms, whether oral or written. This Agreement may not be 

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  8	 

 
amended or modified except by a written modification signed by you and a duly authorized officer of the Company, with the exception of those changes expressly reserved to the Company’s
discretion in this Agreement. This Agreement is governed by the laws of the state of California, without reference to conflicts of law principles, and it is intended to bind and inure to the benefit of and be enforceable by the Company and its
successors and assigns. If any provision of this Agreement shall be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this Agreement, and such provision will be reformed,
construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this Agreement, no waiver of any right hereunder shall be
effective unless it is in writing. Any ambiguity in this Agreement shall not be construed against either party as the drafter. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures
shall be equivalent to original signatures. 
 This offer is subject to satisfactory proof of your identity and right to work in the United States
and other applicable pre-employment screenings. 
 To confirm your terms of employment, please sign and date
this Agreement and the Confidentiality Agreement and return the fully signed documents to Jennifer Bush at jbush@artivabio.com. Please let me know if you have any questions. 

Sincerely, 
 ARTIVA
BIOTHERAPEUTICS, INC. 
  

									
	 By:
	 	 /s/ Peter Flynn, PhD
	 		 		 	
	 Peter Flynn, PhD
	 		 		 	
	 Chief Operating Officer
	 		 		 	
	  
 Reviewed, Understood, and Accepted:
	 		 		 	
	  
 /s/ Chris
Horan
	 		 		 	 12/7/2021

	             Chris Horan
	 		 		 	Date

  

					
	 Artiva
Biotherapeutics, Inc.  |  4747 Executive Drive, Suite 1150, San Diego CA
	  	 	//  9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]